|Slideshows|May 19, 2022

Must Sees in New Orleans: Things to Check Out During 2022 APA

If you're attending APA 2022 in New Orleans, here are some other things to check out in the city.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Should Solitude Be a Psychiatric Value?

ByRonald W. Pies, MD

October 23rd 2025

Preliminary Report on Dangers of AI Chatbots

ByAllen Frances, MD,Luciana Ramos

October 7th 2025

“By His Own Hand”: Socrates’ Suicide as an Affirmative Choice, A Reply to Rev. Christopher Dreisbach, PhD

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 1st 2025

Artificial Intelligence Will Never Replace Psychiatry—But It Will Try to Destroy It

ByDaniel Morehead, MD

September 18th 2025

No, Antidepressants Do Not Provoke Mass Shootings

ByJames L. Knoll IV, MD,Ronald W. Pies, MD

September 12th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Must Sees in New Orleans: Things to Check Out During 2022 APA

Newsletter

Related Content

Should Solitude Be a Psychiatric Value?

Preliminary Report on Dangers of AI Chatbots

“By His Own Hand”: Socrates’ Suicide as an Affirmative Choice, A Reply to Rev. Christopher Dreisbach, PhD

Artificial Intelligence Will Never Replace Psychiatry—But It Will Try to Destroy It

No, Antidepressants Do Not Provoke Mass Shootings

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State